GILD Latest Press Releases

-- November 4, 2026 --

Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026 Business Wire 9:15 AM

-- November 2, 2026 --

Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow Business Wire 8:30 AM

-- October 30, 2026 --

Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences Business Wire 4:05 PM

-- October 29, 2026 --

Gilead Sciences Announces Third Quarter 2026 Financial Results Business Wire 4:02 PM

-- October 27, 2026 --

Canadians Living with Primary Biliary Cholangitis (PBC) One Step Closer to New Treatment Option as Gilead Reaches Milestone National Agreement for LYVDELZI (seladelpar) PRNewswire 8:01 AM

-- October 26, 2026 --

Gabelli To Host 8th Annual Healthcare Symposium Globe Newswire 8:00 AM

-- October 22, 2026 --

Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD Business Wire 4:05 PM

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting 2026 Business Wire 8:00 AM

-- October 19, 2026 --

Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 Business Wire 8:00 AM

-- October 15, 2026 --

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 Business Wire 4:05 PM

-- September 16, 2026 --

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention Business Wire 8:30 AM

-- September 15, 2026 --

ITOC Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against iTonic Holdings Ltd. PRNewswire 5:23 PM

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean Business Wire 11:10 AM

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat Globe Newswire 9:00 AM

-- September 8, 2026 --

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines Business Wire 1:00 PM

-- August 27, 2026 --

U.S. FDA Approves Gilead's Bixlenvo , a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens Business Wire 5:47 PM

-- August 26, 2026 --

Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences Business Wire 4:05 PM

ITOC Stockholders Have Rights - If You Lost Money Investing in iTonic Holdings Ltd. Contact Robbins LLP for Information About Recovering Your Losses Business Wire 2:20 PM

-- August 24, 2026 --

European Commission Expands Role of Gilead's Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status Business Wire 6:31 AM

-- August 19, 2026 --

Robbins LLP Encourages ITOC Stockholders Who Lost Money Investing in iTonic Holdings Ltd. to Contact the Firm for Information About Leading the Class Action Newsfile 3:04 PM

-- August 14, 2026 --

Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC PRNewswire 6:15 PM

-- August 11, 2026 --

PTHL Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the iTonic Holdings Ltd. (ITOC) Securities Class Action Globe Newswire 10:15 AM

-- August 10, 2026 --

Shareholders who lost money in shares of Pheton Holdings Ltd (NASDAQ: PTHL), now named iTonic Holdings Ltd. (NASDAQ: ITOC), should contact Wolf Haldenstein Immediately Globe Newswire 4:26 PM

-- August 7, 2026 --

PTHL Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against iTonic Holdings Ltd. (ITOC)- Previously Knowns as Pheton Holdings Ltd. (PTHL) PRNewswire 7:00 AM

-- August 4, 2026 --

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results Business Wire 9:41 PM

Gilead Sciences Announces Second Quarter 2026 Financial Results Business Wire 4:01 PM

Shareholder Alert: Robbins LLP Informs Shareholders of the iTonic Holdings Ltd. (ITOC)- Previously Known as Pheton Holdings Ltd. (PTHL)- Class Action Lawsuit Business Wire 2:49 PM

-- July 24, 2026 --

CHMP Recommends Gilead's Trodelvy Plus Keytruda in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer Business Wire 6:26 AM

-- July 21, 2026 --

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 Business Wire 4:05 PM

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy Business Wire 10:00 AM

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure Business Wire 10:00 AM

-- June 24, 2026 --

U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer Business Wire 4:29 PM

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market Globe Newswire 8:30 AM

-- June 23, 2026 --

European Commission Approves Trodelvy as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors Business Wire 7:45 AM

-- June 15, 2026 --

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention Business Wire 4:34 PM

-- June 12, 2026 --

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief Business Wire 8:30 AM

-- June 11, 2026 --

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership Business Wire 8:30 AM

-- June 8, 2026 --

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment Business Wire 4:35 PM

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study Business Wire 4:30 PM

-- June 5, 2026 --

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa Business Wire 3:00 AM

-- June 4, 2026 --

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline Business Wire 4:15 PM

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE Globe Newswire 4:15 PM